Kodiak Sciences Reports Q4 Results, Reiterates Strong Phase 3 Zenkuda Data, Accelerates BLA Timeline

summarizeSummary

Kodiak Sciences reported Q4 2025 financial results, including an increased net loss, but confirmed a cash runway into 2027 following a $173 million equity offering, while reiterating strong Phase 3 Zenkuda data and announcing an accelerated BLA submission timeline.

check_boxKey Events

• Q4 and Full Year 2025 Financial Results

  Kodiak Sciences reported a net loss of $56.7 million, or $1.04 per share, for Q4 2025, compared to a net loss of $44.1 million, or $0.84 per share, for Q4 2024. R&D expenses increased to $45.5 million from $31.8 million year-over-year, driven by increased clinical activities.

• Extended Cash Runway and Equity Offering

  The company ended 2025 with $209.9 million in cash and cash equivalents, which is expected to support operations into 2027. This runway was bolstered by a follow-on equity offering completed in December 2025, which raised $173.0 million in net proceeds from the sale of 8 million shares at $23.00 per share.

• Positive Phase 3 GLOW2 Results for Zenkuda Reiterated

  The filing reiterates positive topline results from the GLOW2 Phase 3 study for Zenkuda (tarcocimab tedromer) in diabetic retinopathy, demonstrating superiority over sham with 62.5% of patients achieving a ≥2-step improvement in DRSS compared to 3.3% for sham. This data was previously announced on March 26, 2026.

• Accelerated BLA Submission Timeline for Zenkuda

  Based on the strong efficacy, safety, and durability data from the GLOW2 study, Kodiak Sciences intends to accelerate the Biologics License Application (BLA) submission timeline for Zenkuda, aiming for a multi-indication BLA-ready profile.

auto_awesomeAnalysis

This 8-K provides the formal financial results for Q4 and full year 2025, showing an increased net loss but also an extended cash runway into 2027, supported by a recent $173 million equity offering. Crucially, the filing reiterates the highly positive Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy, which were previously announced, and highlights the company's intent to accelerate the multi-indication Biologics License Application (BLA) submission. This combination of financial stability and strong clinical progress, particularly the accelerated BLA timeline, is a significant positive for the company's long-term outlook.